Bio-Techne Q4 revenue beats estimates; Merck KGaA acquisition keeps stock near $73 offer price.

Bio-Techne reported Q4 revenues of $321.2 million, slightly surpassing estimates, but its adjusted EPS fell 1.9% year-over-year to $0.52, showing mixed financial results. The company's stock remains close to Merck KGaA's $73 per share acquisition offer, limiting price movement despite strong 8% organic growth in Diagnostics and Spatial Biology segments. Benchmark maintains a "Hold" rating due to the pending acquisition, reflecting expectations of stable stock performance until the deal concludes.